Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Steffen, Halbgebauer"'
Autor:
Lorenzo Barba, Christoph Vollmuth, Samir Abu-Rumeileh, Steffen Halbgebauer, Patrick Oeckl, Petra Steinacker, Alexander M. Kollikowski, Cara Schultz, Judith Wolf, Mirko Pham, Michael K. Schuhmann, Peter U. Heuschmann, Karl Georg Haeusler, Guido Stoll, Hermann Neugebauer, Markus Otto
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-7 (2023)
Abstract We aimed to assess the prognostic value of serum β-synuclein (β-syn), neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) in patients with moderate-to-severe acute ischemic stroke. We measured β-syn, GFAP and NfL in
Externí odkaz:
https://doaj.org/article/e4b568f07c824155bc3dfb236de0636a
Autor:
Samir Abu‐Rumeileh, Lorenzo Barba, Matthias Bache, Steffen Halbgebauer, Patrick Oeckl, Petra Steinacker, Antje Güttler, Jacqueline Keßler, Jörg Illert, Christian Strauss, Dirk Vordermark, Markus Otto
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 10, Iss 10, Pp 1924-1930 (2023)
Abstract We analyzed the longitudinal concentrations and prognostic roles of plasma β‐synuclein (β‐syn), glial fibrillary acidic protein (GFAP), and neurofilament proteins (NfL and NfH) in 33 patients with malignant gliomas, who underwent surgi
Externí odkaz:
https://doaj.org/article/1956c4b3dba54c47bf40b37baa7ca0b4
Autor:
Samir Abu‐Rumeileh, Steffen Halbgebauer, Giuseppe Mario Bentivenga, Lorenzo Barba, Simone Baiardi, Andrea Mastrangelo, Patrick Oeckl, Petra Steinacker, Angela Mammana, Sabina Capellari, Markus Otto, Piero Parchi
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 10, Iss 10, Pp 1904-1909 (2023)
ABSTRACT Beta‐synuclein is a promising cerebrospinal fluid and blood biomarker of synaptic damage. Here we analysed its accuracy in the discrimination between sporadic Creutzfeldt–Jakob disease (n = 150) and non‐prion rapidly progressive dement
Externí odkaz:
https://doaj.org/article/52a33a1818cf4c2bb6da062a254fc2c1
Autor:
Steffen Halbgebauer, Petra Steinacker, Daniel Riedel, Patrick Oeckl, Sarah Anderl-Straub, Jolina Lombardi, Christine A. F. von Arnim, Magdalena Nagl, Armin Giese, Albert C. Ludolph, Markus Otto
Publikováno v:
Alzheimer’s Research & Therapy, Vol 14, Iss 1, Pp 1-10 (2022)
Abstract Background Visinin-like protein 1 (VILIP-1) belongs to the group of emerging biomarkers with the potential to support the early diagnosis of Alzheimer’s disease (AD). However, studies investigating the differential diagnostic potential in
Externí odkaz:
https://doaj.org/article/e7c1f8700d874f638e655e532d5d46fb
Autor:
Janine Kutzsche, Sarah Schemmert, Tuyen Bujnicki, Christian Zafiu, Steffen Halbgebauer, Victoria Kraemer-Schulien, Marlene Pils, Lara Blömeke, Julia Post, Andreas Kulawik, Dagmar Jürgens, Wolfgang M. Rossberg, Michael Hümpel, Oliver Bannach, Markus Otto, Joseph A. Araujo, Antje Willuweit, Dieter Willbold
Publikováno v:
Heliyon, Vol 9, Iss 8, Pp e18443- (2023)
Disease-modifying therapies to treat Alzheimer's disease (AD) are of fundamental interest for aging humans, societies, and health care systems. Predictable disease progression in transgenic AD models favors preclinical studies employing a preventive
Externí odkaz:
https://doaj.org/article/92b85f56a79242e6b70799d46bdbe37e
Autor:
Badrieh Fazeli, André Huss, Nerea Gómez de San José, Markus Otto, Hayrettin Tumani, Steffen Halbgebauer
Publikováno v:
Frontiers in Molecular Biosciences, Vol 10 (2023)
Introduction: A rapid and reliable detection of glial fibrillary acidic protein (GFAP) in biological samples could assist in the diagnostic evaluation of neurodegenerative disorders. Sensitive assays applicable in the routine setting are needed to va
Externí odkaz:
https://doaj.org/article/df203ff65f1b4597a31dec2015aa387b
Autor:
Simon Witzel, Felix Frauhammer, Petra Steinacker, David Devos, Pierre-François Pradat, Vincent Meininger, Steffen Halbgebauer, Patrick Oeckl, Joachim Schuster, Simon Anders, Johannes Dorst, Markus Otto, Albert C. Ludolph
Publikováno v:
Translational Neurodegeneration, Vol 10, Iss 1, Pp 1-12 (2021)
Abstract Background Interventional trials in amyotrophic lateral sclerosis (ALS) suffer from the heterogeneity of the disease as it considerably reduces statistical power. We asked if blood neurofilament light chains (NfL) could be used to anticipate
Externí odkaz:
https://doaj.org/article/885330fea1d344a7b200e9e29d421b8e
Autor:
Samir Abu‐Rumeileh, Steffen Halbgebauer, Petra Steinacker, Sarah Anderl‐Straub, Barbara Polischi, Albert C. Ludolph, Sabina Capellari, Piero Parchi, Markus Otto
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 7, Iss 2, Pp 191-199 (2020)
Abstract Objective SerpinA1 (alpha‐1 antitrypsin) is an acute inflammatory protein, which seems to play a role in neurodegeneration and neuroinflammation. In Alzheimer’s disease and synucleinopathies, SerpinA1 is overexpressed in the brain and th
Externí odkaz:
https://doaj.org/article/49cf9e211bd44236b6e58b06945ffde4
Autor:
Lorenzo Barba, Samir Abu-Rumeileh, Steffen Halbgebauer, Giovanni Bellomo, Federico Paolini Paoletti, Lorenzo Gaetani, Patrick Oeckl, Petra Steinacker, Federico Massa, Lucilla Parnetti, Markus Otto
Publikováno v:
Neurology 101(1), e50-e62 (2023). doi:10.1212/WNL.0000000000207371
Background and Objectives.Patients with Lewy body disease (LBD) often show a co-occurring Alzheimer’s disease (AD) pathology. Cerebrospinal fluid (CSF) biomarkers allow the detectionin vivoof AD-related pathological hallmarks included in the AT(N)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::404532704a70289ed4c820441478de92
https://doi.org/10.1212/wnl.0000000000207371
https://doi.org/10.1212/wnl.0000000000207371
Autor:
Patrick Oeckl, Sarah Anderl-Straub, Christine A F Von Arnim, Inês Baldeiras, Janine Diehl-Schmid, Timo Grimmer, Steffen Halbgebauer, Anna M Kort, Marisa Lima, Tainá M Marques, Marion Ortner, Isabel Santana, Petra Steinacker, Marcel M Verbeek, Alexander E Volk, Albert C Ludolph, Markus Otto
Publikováno v:
Journal of neurology, neurosurgery, and psychiatry 93, 659-667 (2022). doi:10.1136/jnnp-2021-328547
ObjectiveReactive astrogliosis is a hallmark of Alzheimer’s disease (AD) and frontotemporal dementia (FTD) but differences between the diseases and time course are unclear. Here, we used serum levels of the astroglial marker glial fibrillary acidic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5095441fef6bb4a2070641f9aef44c0d
https://doi.org/10.1136/jnnp-2021-328547
https://doi.org/10.1136/jnnp-2021-328547